Key Stats for GE HealthCare Stock
- Price change for GE HealthCare stock: -13%
- $GEHC Share Price as of Apr. 29: $59
- 52-Week High: $90
- $GEHC Stock Price Target: $91
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
GE HealthCare (GEHC) stock fell 13% yesterday after the company reported Q1 earnings that missed expectations and cut its full-year profit outlook.
- Adjusted EPS came in at $0.99, missing the $1.05 estimate by about 7.5%. That’s also down from a year ago.
- Revenue was actually a bright spot, coming in at $5.13 billion, up 7.4% year-over-year and slightly ahead of forecasts.
- But on Wall Street, the profit miss and the guidance cut are what matter most.
- For the full year, GE HealthCare now expects adjusted EPS of $4.80 to $5.00. That’s down from the prior range of $4.95 to $5.15.
- Management pointed to three main problems eating into margins: tariff costs, a supplier quality issue in its Pharmaceutical Diagnostics segment, and weaker performance in its Patient Care Solutions division.
CFO Jay Saccaro laid it out plainly on the call. About $250 million in gross inflation headwinds are hitting the business this year, driven mainly by higher memory chip prices and rising oil and freight costs.
The company expects to offset more than half of that through price increases and cost cuts, but not all of it, and not quickly enough to protect near-term earnings.
Net income margin dropped to 7.6%, down 420 basis points from a year ago.
See analysts’ growth forecasts and price targets for GE HealthCare stock (It’s free) >>>
What the Market Is Telling Us About GE HealthCare Stock
GE HealthCare stock was already down about 16.5% year-to-date before today, so this earnings miss adds more pain to an already tough stretch.
The market clearly didn’t like the guidance cut, even though management tried to frame it as a prudent, one-time reset driven by inflation rather than a structural problem.
There are genuine reasons to stay patient.
- Revenue growth held up.
- Orders grew and the backlog hit a record $21.8 billion.
- New imaging products are gaining traction.
- The company’s cardiac imaging drug, Flyrcado, is ramping steadily toward a $500 million annual revenue target by 2028.
But for now, GE HealthCare stock is being punished for lowering the bar. Investors will want to see the promised margin recovery actually show up in second-half results before regaining confidence.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does GE HealthCare Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
